NFAT1 Supports Tumor-induced Anergy of CD4+ T Cells

被引:34
作者
Abe, Brian T. [1 ]
Shin, Daniel S. [1 ]
Mocholi, Enric [1 ]
Macian, Fernando [1 ]
机构
[1] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA
基金
美国国家卫生研究院;
关键词
LARGE ESTABLISHED MELANOMA; ANTIGEN-PRESENTING CELLS; E3 UBIQUITIN LIGASE; ANTITUMOR IMMUNITY; SUPPRESSOR-CELLS; GENE-TRANSCRIPTION; CTLA-4; BLOCKADE; DENDRITIC CELLS; TOLERANCE; INDUCTION;
D O I
10.1158/0008-5472.CAN-11-3775
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Cancer cells express antigens that elicit T cell-mediated responses, but these responses are limited during malignant progression by the development of immunosuppressive mechanisms in the tumor microenvironment that drive immune escape. T-cell hyporesponsiveness can be caused by clonal anergy or adaptive tolerance, but the pathophysiological roles of these processes in specific tumor contexts has yet to be understood. In CD4+ T cells, clonal anergy occurs when the T-cell receptor is activated in the absence of a costimulatory signal. Here we report that the key T-cell transcription factor NFAT mediates expression of anergy-associated genes in the context of cancer. Specifically, in a murine model of melanoma, we found that cancer cells induced anergy in antigen-specific CD4+ T-cell populations, resulting in defective production of several key effector cytokines. NFAT1 deficiency blunted the induction of anergy in tumor antigen-specific CD4+ T cells, enhancing antitumor responses. These investigations identified tumor-induced T-cell hyporesponsiveness as a form of clonal anergy, and they supported an important role for CD4+ T-cell anergy in driving immune escape. By illustrating the dependence of tumor-induced CD4+ T-cell anergy on NFAT1, our findings open the possibility of targeting this transcription factor to improve the efficacy of cancer immunotherapy or immunochemotherapy. Cancer Res; 72(18); 4642-51. (C) 2012 AACR.
引用
收藏
页码:4642 / 4651
页数:10
相关论文
共 49 条
[1]
GRAIL:: An E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells [J].
Anandasabapathy, N ;
Ford, GS ;
Bloom, D ;
Holness, C ;
Paragas, V ;
Seroogy, C ;
Skrenta, H ;
Hollenhorst, M ;
Fathman, CG ;
Soares, L .
IMMUNITY, 2003, 18 (04) :535-547
[2]
Regulation of T-cell tolerance by calcium/NFAT signaling [J].
Baine, Ian ;
Abe, Brian T. ;
Macian, Fernando .
IMMUNOLOGICAL REVIEWS, 2009, 231 :225-240
[3]
Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells [J].
Bandyopadhyay, Sanmay ;
Dure, Myrianne ;
Paroder, Monika ;
Soto-Nieves, Noemi ;
Puga, Irene ;
Macian, Fernando .
BLOOD, 2007, 109 (07) :2878-2886
[4]
NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells [J].
Bopp, T ;
Palmetshofer, A ;
Serfling, E ;
Heib, V ;
Schmitt, S ;
Richter, C ;
Klein, M ;
Schild, H ;
Schmitt, E ;
Stassen, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (02) :181-187
[5]
Adaptive tolerance and clonal anergy are distinct biochemical states [J].
Chiodetti, L ;
Choi, S ;
Barber, DL ;
Schwartz, RH .
JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2279-2291
[6]
Cuenca A, 2003, CANCER RES, V63, P9007
[7]
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[8]
ENHANCED IN-VIVO GROWTH AND RESISTANCE TO REJECTION OF TUMOR-CELLS EXPRESSING DOMINANT-NEGATIVE IFN-GAMMA RECEPTORS [J].
DIGHE, AS ;
RICHARDS, E ;
OLD, LJ ;
SCHREIBER, RD .
IMMUNITY, 1994, 1 (06) :447-456
[9]
Costimulatory and coinhibitory receptors in anti-tumor immunity [J].
Driessens, Gregory ;
Kline, Justin ;
Gajewski, Thomas F. .
IMMUNOLOGICAL REVIEWS, 2009, 229 :126-144
[10]
Enk AH, 1997, INT J CANCER, V73, P309, DOI 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO